Asgard Therapeutics

Rwanda
Byumba, Northern Province, Rwanda, 221 84

Company profile

Asgard Therapeutics company profile

Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen-presenting cells.

Business identity

Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2018-01-01, Year

Headquarters

Postal code
221 84
Country code
RW
Continent
Africa

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
3
Total equity funding
$39.6M
Last funding
Series A / $32.6M / 2024-03-14
Last equity funding
Series A / $32.6M
Investors
6
Lead investors
5
Founders
3
Articles
21

Founders and investors

Founders

Cristiana PiresFábio RosaFilipe Pereira

Lead investors

Boehringer Ingelheim Venture FundIndustrifondenJohnson & Johnson InnovationNovo HoldingsRV Invest

Investors

Boehringer Ingelheim Venture FundIndustrifondenJohnson & Johnson InnovationNovo HoldingsRV Invest